{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:03:19Z","timestamp":1785146599841,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Valproic acid (VPA) is frequently used together with clozapine (CLZ) as mood-stabilizer or for the prevention of seizures in patients with psychotic disorders. VPA is known to reduce levels of the pharmacologically active CLZ-metabolite <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethylclozapine (<jats:italic toggle=\"yes\">N<\/jats:italic>-DMC), but factors determining the degree of this interaction are unknown. Here, we investigated the relationship between VPA dose and serum concentration on <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC levels in a large patient population adjusting for sex, age, and smoking habits as covariates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 763 patients with steady-state serum concentrations of CLZ and <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC concurrently using VPA (cases, n = 76) or no interacting drugs (controls, n = 687) were retrospectively included from a therapeutic drug monitoring service at Diakonhjemmet Hospital, Oslo, between March 2005 and December 2016. In addition to information about prescribed doses, age, sex, smoking habits, and use of other interacting drugs were obtained. The effects of VPA dose and serum concentration on dose-adjusted <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC levels were evaluated by univariate correlation and multivariate linear mixed-model analyses adjusting for covariates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The dose-adjusted <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC levels were approximately 38% lower in VPA users (cases) versus nonusers (controls) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Within the VPA cases, a negatively correlation between VPA dose and dose-adjusted <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC levels was observed with an estimated reduction of 1.42% per 100-mg VPA dose (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.033) after adjusting for sex, age, and smoking. By contrast, there was no correlation between VPA serum concentration and dose-adjusted <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC levels (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.873).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The study shows that VPA dose, not concentration, is of relevance for the degree of reduction in <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC level in clozapine-treated patients. Presystemic induction of UGT enzymes or efflux transporters might underlie the reduction in <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC level during concurrent use of VPA. Our findings indicate that a VPA daily dose of 1500 mg or higher provides a further 21% reduction in <jats:italic toggle=\"yes\">N<\/jats:italic>-DMC concentration. This is likely a relevant change in the exposure of this active metabolite where low levels are associated with implications of CLZ therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000619","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:38:45Z","timestamp":1561729125000},"page":"503-508","source":"Crossref","is-referenced-by-count":23,"title":["Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid\u2014Indications of a Presystemic Interaction Mechanism"],"prefix":"10.1097","volume":"41","author":[{"given":"Robert L.","family":"Smith","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Kylles\u00f8","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Haslemo","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Andreas","family":"Andreassen","sequence":"additional","affiliation":[{"name":"NORMENT and K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40263-014-0222-y","article-title":"Seizure associated with clozapine: incidence, etiology, and management","volume":"29","author":"Williams","year":"2015","journal-title":"CNS Drugs."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level relationships","volume":"1","author":"Varma","year":"2011","journal-title":"Ther Adv Psychopharmacol."},{"key":"R5-20230814","first-page":"255","article-title":"Concurrent use of clozapine and valproate in affective and psychotic disorders","volume":"55","author":"Kando","year":"1994","journal-title":"J Clin Psychiatry."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","article-title":"Sodium valproate and clozapine induced neutropenia: a case control study using register data","volume":"195","author":"Malik","year":"2018","journal-title":"Schizophr Res."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1046\/j.1440-1614.2001.0911f.x","article-title":"Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine","volume":"35","author":"Pantelis","year":"2001","journal-title":"Aust N Z J Psychiatry."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism","volume":"47","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JCP.0000000000000877","article-title":"Comedication of valproic acid is associated with increased metabolism of clozapine","volume":"38","author":"Hommers","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb04786.x","article-title":"N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis","volume":"86","author":"Gerson","year":"1994","journal-title":"Br J Haematol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s40263-017-0469-1","article-title":"Correlation between serum concentrations of N-desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study","volume":"31","author":"Smith","year":"2017","journal-title":"CNS Drugs."},{"key":"R12-20230814","first-page":"603","article-title":"Biotransformation of clozapine in humans","volume":"25","author":"Dain","year":"1997","journal-title":"Drug Metab Dispos."},{"key":"R13-20230814","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2017","journal-title":"Pharmacopsychiatry."},{"key":"R14-20230814","first-page":"524","article-title":"N-oxygenation of clozapine by flavin-containing monooxygenase","volume":"25","author":"Tugnait","year":"1997","journal-title":"Drug Metab Dispos."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1124\/dmd.112.050484","article-title":"Characterization of human cytochrome P450s involved in the bioactivation of clozapine","volume":"41","author":"Dragovic","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.toxlet.2016.06.013","article-title":"What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?","volume":"258","author":"Wagmann","year":"2016","journal-title":"Toxicol Lett."},{"key":"R17-20230814","first-page":"984","article-title":"Metabolism and bioactivation of clozapine by human liver in vitro","volume":"272","author":"Pirmohamed","year":"1995","journal-title":"J Pharmacol Exp Ther."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","article-title":"UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation","volume":"33","author":"Mori","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. An update","volume":"36","author":"Zevin","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FPC.0b013e32835c3b48","article-title":"Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption","volume":"23","author":"Bloom","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab Rev."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/FTD.0000000000000513","article-title":"Effect of valproate and antidepressant drugs on clozapine metabolism in patients with psychotic mood disorders","volume":"40","author":"Marazziti","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3182693d2a","article-title":"Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking","volume":"34","author":"Haslemo","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2014implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.bjp.0706830","article-title":"The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver","volume":"149","author":"Eyal","year":"2006","journal-title":"Br J Pharmacol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.1991.tb03908.x","article-title":"Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients","volume":"32","author":"Tartara","year":"1991","journal-title":"Br J Clin Pharmacol."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0005-2760(98)00115-5","article-title":"UDP-glucuronosyltransferases in human intestinal mucosa","volume":"1394","author":"Radominska-Pandya","year":"1998","journal-title":"Biochim Biophys Acta."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1073\/pnas.0402014101","article-title":"Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition","volume":"101","author":"Jansen","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.115.065714","article-title":"Drug metabolism by the host and gut microbiota: a partnership or rivalry?","volume":"43","author":"Swanson","year":"2015","journal-title":"Drug Metab Dispos."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie.\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007691-200012000-00003","article-title":"Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?","volume":"22","author":"Morris","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jphp.12209","article-title":"Interactions between valproic acid and quetiapine\/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring","volume":"66","author":"Vella","year":"2014","journal-title":"J Pharm Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:20:38Z","timestamp":1692051638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201908000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000619","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}